Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "IRA"

1454 News Found

Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain
People | September 03, 2024

Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain

Birajeev is a seasoned Supply Chain leader with an experience of 23 years


Roche closes acquisition of LumiraDx’s Point of Care technology
News | August 05, 2024

Roche closes acquisition of LumiraDx’s Point of Care technology

The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances


Piramal Pharma Q1 FY25 net loss narrows
News | July 26, 2024

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24


Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan
News | July 14, 2024

Moderna and Mitsubishi Tanabe Pharma ink agreement to promote Moderna’s mRNA respiratory vaccine portfolio in Japan

The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed


Cipla invests additional Rs. 26 crore in Achira
News | May 16, 2024

Cipla invests additional Rs. 26 crore in Achira

Achira is engaged in development and commercialization of PoC medical test kits in India


Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr
News | May 11, 2024

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024


Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta
News | May 09, 2024

Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta

the campaign emphasizes the brand's reliability and effectiveness in providing timely relief


AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
Clinical Trials | May 02, 2024

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024

New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD


Lupin launches Mirabegron Extended-Release Tablets in US
Drug Approval | April 22, 2024

Lupin launches Mirabegron Extended-Release Tablets in US

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US